The FINANCIAL -- ADOCIA, a key player in regenerative medicine and treatment of chronic diseases, today celebrated its listing on NYSE Euronext in Paris.

Founded in 2005, ADOCIA designed and developed BioChaperone, a proprietary technology platform that improves the therapeutic performance of proteins such as insulin and the growth factors used to treat diabetes and chronic wounds.

According to NYSE Euronext, the company has several promising products in its portfolio and is currently working in two development partnerships with pharmaceutical companies that rank among the very largest in the industry. It recently signed an exclusive worldwide license with a major company to develop an ultra-fast-acting insulin analogue, an agreement that involves milestone payments that could total as much as $166 million. ADOCIA is based in Lyon and has 49 employees, with 80% working in Research & Development.

ADOCIA was listed through the admission to trading of 4,458,710 existing shares and 1,592,798 new shares issued under a Global Offering, including full exercise of the extension clause. The Global Offering raised a total of €25.3 million, which could rise to €29.1 million if the Over-allotment option is fully exercised.

The admission and issue price of ADOCIA shares was set at €15.88. Market capitalisation stood at around €96.1 million on the day of listing.

Related Stories

• UPDATE: OIL DATA: China April Iran Crude Imports Rise Vs February, March
• UK Deputy PM: Euro-Zone Inaction Will Fuel Extremism - Report
• ICAP Appoints Ex-Citigroup Coyne To Head Traiana